Drugs / Bleximenib
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05521087 | Dec 2025 → Sep 2026 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | Janssen Research & Development, LLC | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT07295951 | Nov 2025 → Jul 2026 | acute lymphoblastic leukemia, acute myeloid leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05453903 | Oct 2022 → Oct 2026 expected | acute myeloid leukemia | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04811560 | May 2021 → Feb 2027 expected | acute leukemia | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03013998 | Nov 2016 → Dec 2032 expected | acute myeloid leukemia | Beat AML, LLC | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07223814 | Mar 2026 → Jun 2030 expected | acute myeloid leukemia | HOVON Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT06852222 | Jun 2025 → Jun 2029 expected | acute myeloid leukemia | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-12 | Janssen Research & Development, LLC | Results New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia jnj.com ↗
“These data highlight the potential of this targeted therapy in combination with VEN + AZA for patients with newly diagnosed AML who are ineligible for intensive chemotherapy or with disease that has relapsed after prior therapy.” |
| 2025-06-12 | Janssen Research & Development, LLC | Results New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia jnj.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-12 | Janssen Research & Development, LLC | New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia jnj.com ↗ |
| 2025-06-12 | Janssen Research & Development, LLC | New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia jnj.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bleximenib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04811560 ↗ |
| Known as | JNJ-75276617 | “JNJ-75276617 (bleximenib) is a novel, orally bioavailable, potent, and selective protein-protein interaction inhibitor of the binding between menin and KMT2A.” PMID 38905635 ↗ Sep 2024 |
| Action | Inhibit | “protein-protein interaction inhibitor of the binding between menin and KMT2A” PMID 38905635 ↗ Sep 2024 |
| Modality | Small molecule | — CHEMBL5314509 ↗ |
| Route | Oral | “Bleximenib is administered orally.” NCT04811560 ↗ |
| Target | KMT2A | “protein-protein interaction inhibitor of the binding between menin and KMT2A” PMID 38905635 ↗ Sep 2024 |